vs

Side-by-side financial comparison of ChargePoint Holdings, Inc. (CHPT) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $105.7M, roughly 1.6× ChargePoint Holdings, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 6.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -4.5%).

ChargePoint Holdings, Inc. is an American electric vehicle infrastructure company based in Campbell, California. ChargePoint operates the largest online network of independently owned EV charging stations operating in 14 countries and makes some of its technology.

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

CHPT vs ESPR — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.6× larger
ESPR
$168.4M
$105.7M
CHPT
Growing faster (revenue YoY)
ESPR
ESPR
+137.6% gap
ESPR
143.7%
6.1%
CHPT
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-4.5%
CHPT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CHPT
CHPT
ESPR
ESPR
Revenue
$105.7M
$168.4M
Net Profit
$-52.5M
Gross Margin
30.7%
Operating Margin
-42.0%
50.6%
Net Margin
-49.7%
Revenue YoY
6.1%
143.7%
Net Profit YoY
32.4%
EPS (diluted)
$-2.23
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHPT
CHPT
ESPR
ESPR
Q4 25
$105.7M
$168.4M
Q3 25
$98.6M
$87.3M
Q2 25
$97.6M
$82.4M
Q1 25
$101.9M
$65.0M
Q4 24
$99.6M
$69.1M
Q3 24
$108.5M
$51.6M
Q2 24
$107.0M
$73.8M
Q1 24
$115.8M
$137.7M
Net Profit
CHPT
CHPT
ESPR
ESPR
Q4 25
$-52.5M
Q3 25
$-66.2M
$-31.3M
Q2 25
$-57.1M
$-12.7M
Q1 25
$-58.8M
$-40.5M
Q4 24
$-77.6M
Q3 24
$-68.9M
$-29.5M
Q2 24
$-71.8M
$-61.9M
Q1 24
$-94.7M
$61.0M
Gross Margin
CHPT
CHPT
ESPR
ESPR
Q4 25
30.7%
Q3 25
31.2%
Q2 25
28.7%
Q1 25
28.2%
Q4 24
22.9%
Q3 24
23.6%
Q2 24
22.1%
Q1 24
19.3%
Operating Margin
CHPT
CHPT
ESPR
ESPR
Q4 25
-42.0%
50.6%
Q3 25
-59.8%
-11.4%
Q2 25
-55.1%
8.6%
Q1 25
-53.9%
-34.0%
Q4 24
-68.4%
-6.4%
Q3 24
-57.8%
-31.0%
Q2 24
-62.7%
3.5%
Q1 24
-80.2%
52.5%
Net Margin
CHPT
CHPT
ESPR
ESPR
Q4 25
-49.7%
Q3 25
-67.1%
-35.9%
Q2 25
-58.5%
-15.4%
Q1 25
-57.7%
-62.2%
Q4 24
-77.9%
Q3 24
-63.5%
-57.2%
Q2 24
-67.1%
-83.9%
Q1 24
-81.8%
44.3%
EPS (diluted)
CHPT
CHPT
ESPR
ESPR
Q4 25
$-2.23
$0.32
Q3 25
$-2.85
$-0.16
Q2 25
$-0.12
$-0.06
Q1 25
$-5.83
$-0.21
Q4 24
$-3.56
$-0.14
Q3 24
$-3.22
$-0.15
Q2 24
$-0.17
$-0.33
Q1 24
$-23.36
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHPT
CHPT
ESPR
ESPR
Cash + ST InvestmentsLiquidity on hand
$180.5M
$167.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$38.4M
$-302.0M
Total Assets
$848.0M
$465.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHPT
CHPT
ESPR
ESPR
Q4 25
$180.5M
$167.9M
Q3 25
$194.1M
$92.4M
Q2 25
$195.9M
$86.1M
Q1 25
$224.6M
$114.6M
Q4 24
$219.4M
$144.8M
Q3 24
$243.3M
$144.7M
Q2 24
$261.9M
$189.3M
Q1 24
$327.4M
$226.6M
Stockholders' Equity
CHPT
CHPT
ESPR
ESPR
Q4 25
$38.4M
$-302.0M
Q3 25
$70.7M
$-451.4M
Q2 25
$118.6M
$-433.5M
Q1 25
$137.5M
$-426.2M
Q4 24
$181.0M
$-388.7M
Q3 24
$230.9M
$-370.2M
Q2 24
$277.9M
$-344.2M
Q1 24
$327.7M
$-294.3M
Total Assets
CHPT
CHPT
ESPR
ESPR
Q4 25
$848.0M
$465.9M
Q3 25
$870.3M
$364.0M
Q2 25
$897.6M
$347.1M
Q1 25
$898.2M
$324.0M
Q4 24
$966.3M
$343.8M
Q3 24
$1.0B
$314.1M
Q2 24
$1.1B
$352.3M
Q1 24
$1.1B
$373.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHPT
CHPT
ESPR
ESPR
Operating Cash FlowLast quarter
$-22.5M
$45.2M
Free Cash FlowOCF − Capex
$-23.6M
FCF MarginFCF / Revenue
-22.3%
Capex IntensityCapex / Revenue
1.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHPT
CHPT
ESPR
ESPR
Q4 25
$-22.5M
$45.2M
Q3 25
$-6.2M
$-4.3M
Q2 25
$-33.0M
$-31.4M
Q1 25
$-2.7M
$-22.6M
Q4 24
$-30.6M
$-35.0M
Q3 24
$-51.2M
$-35.3M
Q2 24
$-62.5M
$-7.2M
Q1 24
$-41.5M
$53.8M
Free Cash Flow
CHPT
CHPT
ESPR
ESPR
Q4 25
$-23.6M
Q3 25
$-7.5M
Q2 25
$-34.0M
Q1 25
$-4.6M
Q4 24
$-33.4M
Q3 24
$-55.0M
$-35.5M
Q2 24
$-66.0M
$-7.3M
Q1 24
$-46.2M
$53.8M
FCF Margin
CHPT
CHPT
ESPR
ESPR
Q4 25
-22.3%
Q3 25
-7.6%
Q2 25
-34.9%
Q1 25
-4.5%
Q4 24
-33.5%
Q3 24
-50.7%
-68.7%
Q2 24
-61.7%
-9.9%
Q1 24
-39.9%
39.0%
Capex Intensity
CHPT
CHPT
ESPR
ESPR
Q4 25
1.0%
0.0%
Q3 25
1.3%
0.0%
Q2 25
1.1%
0.0%
Q1 25
1.9%
0.0%
Q4 24
2.8%
0.0%
Q3 24
3.5%
0.3%
Q2 24
3.2%
0.1%
Q1 24
4.1%
0.1%
Cash Conversion
CHPT
CHPT
ESPR
ESPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHPT
CHPT

Products$56.4M53%
License And Service$42.0M40%
Other$7.3M7%

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

Related Comparisons